Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.…
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Virax Biolabs Group (NASDAQ: VRAX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 26 employees.
The shares were at 0.3319 USD on 20 November 2026, down 97.2% over 52 weeks. Its 52-week range is 0.2928 USD to 21.75 USD: the price is 98.5% below the high and 13.4% above the low.
Its market capitalisation is 446.40K USD.
Virax Biolabs Group reports return on equity of -66.3% and revenue up 684.9% year over year.
It holds more cash than debt, a net cash position of 6.10M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.
No upcoming events tracked.